8-K: Onconetix Faces Nasdaq Delisting Threat Due to 10-K Filing Delay and Low Stock Price

Onconetix, Inc. received a delisting notice from Nasdaq for failing to file its annual report and not meeting the minimum bid price requirement.

Summary

• Onconetix, Inc. received a deficiency notice from Nasdaq on April 24, 2025, because it failed to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• This failure violates Nasdaq Listing Rule 5250(c)(1).
• The company was previously notified on April 18, 2025, that it was not in compliance with the minimum bid price rule (Nasdaq Listing Rule 5550(a)(2)) because its stock price remained below $1.00 per share from November 25, 2024, to January 10, 2025.
• On April 14, 2025, Nasdaq issued a notice that the company's securities had a closing bid price of $0.10 or less for ten consecutive trading days and was subject to delisting pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii).
• Onconetix requested a hearing before the Nasdaq Hearings Panel, which has been scheduled for May 27, 2025.
• The company intends to request a stay of the suspension by May 1, 2025.
• Onconetix is working to finalize and file the 10-K as soon as practicable, prior to the hearing date.
• The company issued a press release on April 30, 2025, disclosing the receipt of the delisting notice.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to the delisting notice and non-compliance with Nasdaq listing rules. The company faces significant challenges in regaining compliance and avoiding delisting.

Positives

• Onconetix has requested a hearing before the Nasdaq Hearings Panel, which has stayed the trading suspension pending the Panel's decision.
• The company intends to request a stay of the suspension by May 1, 2025, which would further delay any potential delisting.
• Onconetix is actively working to finalize and file the 10-K as soon as practicable.

Negatives

• Onconetix received a delisting notice from Nasdaq for failing to file its 10-K.
• The company is also non-compliant with the minimum bid price rule, as its stock price has fallen below $1.00.
• There is no assurance that the Panel will grant the Company's request for a stay pending the hearing process or any further extension following the hearing.

Risks

• Failure to file the 10-K could result in delisting from Nasdaq.
• Failure to regain compliance with the minimum bid price rule could also result in delisting.
• The Nasdaq Hearings Panel may not grant the company's request for a stay of suspension.
• The company's stock price may continue to decline.

Future Outlook

The company intends to submit a stay request on or before May 1, 2025, and is working diligently to finalize and file the 10-K as soon as practicable on or prior to the hearing date.

Management Comments

• The Company intends to file the Form 10-K as promptly as possible in order to regain compliance with the Rule.

Industry Context

Delisting notices are not uncommon for companies that fail to meet Nasdaq's listing requirements, particularly those with low stock prices or delayed financial filings. This situation highlights the importance of maintaining compliance with exchange regulations to avoid potential negative impacts on investor confidence and access to capital.

Comparison to Industry Standards

• Many biotechnology companies, especially smaller ones, face challenges in maintaining Nasdaq listing compliance due to volatile stock prices and the need for timely financial reporting.
• Companies like Geron Corporation and Omeros Corporation have faced similar delisting warnings in the past due to low stock prices, requiring them to implement strategies such as reverse stock splits to regain compliance.
• The delay in filing the 10-K is a more serious issue, as it indicates potential internal control weaknesses or accounting issues, similar to what has been seen in companies like Sino-Global Shipping America, Ltd., which faced delisting due to accounting irregularities.

Stakeholder Impact

• Shareholders face the risk of delisting, which could negatively impact the stock price.
• Employees may experience uncertainty due to the company's financial challenges.
• The company's reputation may be damaged, potentially affecting relationships with customers and suppliers.

Next Steps

• Onconetix intends to submit a stay request on or before May 1, 2025.
• Onconetix is working to finalize and file the 10-K as soon as practicable on or prior to the hearing date of May 27, 2025.

Key Dates

Keywords

delisting, Nasdaq, 10-K, compliance, minimum bid price, Onconetix, ONCO